Valuation: Autolus Therapeutics plc

Market Cap 397M 345M 321M 295M 556M 37.86B 565M 3.78B 1.48B 18.85B 1.49B 1.46B 63.19B P/E 2026 *
-1.68x
P/E 2027 * -2.36x
Enterprise Value 357M 310M 289M 265M 501M 34.08B 509M 3.41B 1.34B 16.97B 1.34B 1.31B 56.89B EV / Sales 2026 *
2.78x
EV / Sales 2027 * 2.33x
Free-Float
3.32%
Yield 2026 *
-
Yield 2027 * -
1 day-2.61%
1 week+2.76%
1 month-5.70%
3 months+1.36%
6 months+8.76%
Current year-25.13%
1 week 1.41
Extreme 1.41
1.58
1 month 1.38
Extreme 1.38
1.74
Current year 1.18
Extreme 1.175
2.07
1 year 1.18
Extreme 1.175
2.52
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap.
29/6/26 Free

Director

79,167 0.0477%
18/3/26 Other

Controller/Auditor

331,000 0.1992%
18/3/26 Other

General Counsel

780,818 0.4700%
Change 5-day change 1-year change 3-year change Capi.($)
-2.61%+2.76%-36.60%-52.70% 397M
+3.29%+16.25%+36.46%+3.19% 76.15B
+2.72%-9.39%+20.58%+172.43% 48.89B
-2.75%+48.50%+48.50%+48.50% 47.83B
-3.81%+7.74%-53.40%-54.31% 41.37B
-2.40%+0.38%+53.81%-24.64% 29.99B
-2.82%+1.57%+58.12%+87.66% 24.23B
-5.35%+1.39%+98.59%-51.89% 21.89B
-1.59%-3.61%-6.77%+150.58% 19.25B
-0.42%+2.89%+77.99%+128.67% 17.14B
Average -1.57%+1.61%+29.73%+40.75% 32.71B
Weighted average by Cap. -0.62%+2.98%+31.38%+43.03%

Financials

2026 *2027 *
Net sales 129M 112M 104M 95.52M 180M 12.27B 183M 1.23B 481M 6.11B 483M 472M 20.49B 191M 166M 155M 142M 268M 18.23B 272M 1.82B 715M 9.08B 717M 701M 30.43B
Net income -242M -211M -196M -180M -340M -23.14B -345M -2.31B -907M -11.52B -910M -890M -38.62B -185M -161M -149M -137M -259M -17.63B -263M -1.76B -691M -8.78B -694M -678M -29.44B
Net Debt -39.53M -34.36M -31.99M -29.37M -55.46M -3.77B -56.32M -377M -148M -1.88B -148M -145M -6.3B 48.41M 42.09M 39.17M 35.97M 67.92M 4.62B 68.97M 462M 181M 2.3B 182M 178M 7.71B
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
31/07/26 USD 1.490 -2.61% 815,256
30/07/26 USD 1.530 +4.79% 1,745,722
29/07/26 USD 1.460 +0.69% 651,988
28/07/26 USD 1.450 -0.68% 527,891
27/07/26 USD 1.460 +0.69% 506,155
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.490USD
Average target price
8.550USD
Spread / Average Target
+473.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock